Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-r
Image Not Found On Media Library
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Pre-Order CRaFT 2025
    • 2024 CRaFT Report
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Highly Productive Month for pCPA Initiations

July 20, 2021
-
Market Access News
-
Posted by MORSE - 5 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): June 2021 Trends and Insights

 

June 2021 Highlights:

  • 8 products completed CADTH review
  • 12 products initiated pCPA negotiations
  • 3 negotiations were completed with an LOI
  • 0 negotiations were closed without an LOI
  • 2 files were closed without negotiation

 

Key Take-Aways:

  • The volume of files under consideration remains stable with a slight decrease in the days under consideration in June relative to the last 6 months. With 8 recommendations coming out of CADTH this month, this has kept the volume of files under consideration stable, despite pCPA initiating a high number of negotiations this month (12).
  • June has been the most productive month for pCPA over the past 12 months with respect to number of negotiations initiated, as well as the number of active negotiations. This has led to a slight drop in the ratio of under consideration to active files.
  • The pCPA has been making strides to deal with files that have been under their purview for extended periods of time. May saw the conclusion of 3 protracted negotiations while June saw similar output with Orkambi and Kalydeco being completed with a LOI after close to a year.
  • With the closure of a number of protracted negotiations over the last 2 months, and the addition of 12 new negotiations initiated, the average duration of negotiation has also dropped to its lowest point (~125 days) over the last 12 months.

 

Files Under pCPA Consideration*:

CADTH issued 8 new recommendations in June (31 files under pCPA consideration as of June 30th – same as 31 in May).

PRODUCT INDICATION SPONSOR Reimbursement Decision Type REC’N* DATE
Zeposia (ozanimod) Multiple Sclerosis, relapsing – remitting Celgene Inc. Do not reimburse Non-oncology 2021-06-23
Ilumya (tildrakizumab) Psoriasis, moderate to severe plaque Sun Pharma Canada Conditional Reimbursement Non-oncology 2021-06-21
Tafinlar & Mekinist in combo (Dabrafenib & Trametinib in combo) NSCLC BRAF V600 Novartis Pharmaceuticals Canada Inc. Conditional Reimbursement Oncology 2021-06-14
Veltassa (patiromer) Hyperkalemia, adults (chronic kidney disease) Otsuka Canada Pharmaceuticals Inc. Conditional Reimbursement Non-oncology 2021-06-08
Reblozyl (luspatercept) beta-thalassemia associated anemia Celgene Inc. / Bristol-Myers Squibb Canada Co. Conditional Reimbursement Non-oncology 2021-06-08
Rybelsus (semaglutide) diabetes mellitus, type 2 Novo Nordisk Canada Inc. Conditional Reimbursement Non-oncology 2021-06-08
Dupixent (dupilumab) Asthma Sanofi-Genzyme Conditional Reimbursement Non-oncology 2021-06-08
Inrebic (fedratinib) Myelofibrosis Celgene Inc. / Bristol-Myers Squibb Canada Co. Conditional Reimbursement Oncology 2021-06-02

*Note: Since MORSE began issuing pCPA updates, we have defined “under pCPA consideration” as the time between receipt of a final recommendation or notification to implement from CADTH. This does not match the date that the pCPA website has recently started to publish (which starts after issuance of the acknowledgement letter which is not publicly available). This is to ensure consistency of data analysis historically.
  

Signals Decoded:

 

The volume of files under consideration remains stable with a slight decrease in the days under consideration in June relative to the last 6 months. With eight recommendations coming out of CADTH this month, this has kept the volume of files under consideration stable, despite pCPA initiating a high number of negotiations this month (12).

 

Negotiation Initiation:

The pCPA initiated 12 new negotiations in June (41 active negotiations as of June 30th) – up from 32 in May.

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Zejula (niraparib) First Line Ovarian Cancer GlaxoSmithKline Inc. Oncology 2021-06-01 18
Remsima SC (Infliximab SC) Rheumatoid arthritis Celltrion Healthcare Canada Ltd. Biosimilar 2021-06-04 43
Enspryng (satralizumab) Neuromyelitis optica spectrum disorder Hoffmann-La Roche Ltd. Non-oncology 2021-06-30 70
Forxiga (Dapagliflozin) Heart failure with reduced ejection fraction AstraZeneca Canada Inc. Non-oncology 2021-06-17 176
Enerzair Breezhaler (indacaterol glycopyrronium mometasone furoate) Asthma maintenance, adults Novartis Pharma Canada Inc. Non-oncology 2021-06-23 211
Atectura Breezhaler (indacaterol/mometasone furoate) Asthma maintenance (adults, children 12 or older) Novartis Pharma Canada Inc. Non-oncology 2021-06-23 211
Insulin pumps and pump supplies Diabetes Mellitus, Type 1 & 2 Multiple manufacturers Other 2021-06-29 N/A
Riabni (rituximab) Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) Amgen Canada Inc. Biosimilar 2021-06-11 N/A
Osnuvo (teriparatide) osteoporosis AVIR Pharma Inc. Biosimilar 2021-06-04 N/A
Bambevi (bevacizumab) Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) – Glioblastoma Apotex Inc. Biosimilar 2021-06-11 N/A
Abevmy (bevacizumab) Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma BGP Pharma ULC Biosimilar 2021-06-11 N/A
Foquest (methylphenidate hydrochloride CR)** Treatment of adult hyperactivity in adults Elvium Life Sciences Other 2021-06-29 N/A

*Time to Initiation (TTI) – Time from final recommendation or notification to implement to pCPA initiation in calendar days
**Initiated and completed on the same day

 

Signals Decoded:
 
June has been the most productive month for pCPA over the past 12 months with respect to number of negotiations initiated, as well as the number of active negotiations. This has led to a slight drop in the ratio of under consideration to active files.

 

Initiated files include: 5 biosimilars, including the first biosimilar for teriparatide, and a category negotiation including multiple manufacturers for insulin pumps and insulin pump supplies. This follows a previous category negotiation on blood glucose test strips.

 

Completed/Closed Negotiations:

The pCPA completed 3 negotiations with a Letter of Intent (LOI) in June 2021, the same number as in May.

PRODUCT INDICATION Sponsor Type Status LOI DATE TTN*
Orkambi (lumacaftor/ivacaftor) Cystic Fibrosis, F508del CFTR mutation Vertex Pharmaceuticals (Canada) Incorporated Other Completed 2021-06-03 356
Kalydeco (Ivacaftor) cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation Vertex Pharmaceuticals (Canada) Incorporated Other Completed 2021-06-03 356
Foquest (methylphenidate hydrochloride CR)** Treatment of adult hyperactivity in adults Elvium Life Sciences Other Completed 2021-06-29 1

* TTN = Time to Negotiate in calendar days
**Initiated and completed on the same day

 

Not Negotiated:

The pCPA declined negotiations on 2 files in June 2021. 

PRODUCT INDICATION Sponsor Type Status Negotiation End DATE TTD*
Odomzo (sonidegib) Basal Cell Carcinoma (BCC) Sun Pharma Canada Inc. Oncology Not Negotiated 2021-06-04 21
Pomalyst (Pomalidomide) Multiple Myeloma (second-line or beyond) Celgene Inc. Oncology Not Negotiated 2021-06-04 610

*TTD = Time to Decline in calendar days

 

Signals Decoded:
 
The pCPA has been making strides to deal with files that have been under their purview for extended periods of time. May saw the conclusion of 3 protracted negotiations while June saw similar output with Orkambi and Kalydeco being completed with a LOI after close to a year.

 

Pomalyst being declined for negotiation after almost 2 years. Pomalyst received a conditional reimbursement recommendation from CADTH in September 2019  and has been under consideration since that time (610 days). It is unclear why it remained under consideration for this extended time period and what prompted the recent closure. Typically, decisions on declining files for negotiation are made relatively quickly (59 days on average in 2020).

 

Foquest, a new formulation of methylphenidate, initated and successfully achieved an LOI in the same day.

 

  

  

  

Signals Decoded:
 
With the closure of a number of protracted negotiations over the last 2 months, and the addition of 12 new negotiations initiated, the average duration of negotiation has also dropped to its lowest point (~125 days) over the last 12 months.
 
Similarly, several files under consideration for extended periods were initiated/declined leading to a drop in the files under consideration for greater than 6 months.

 
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
Files Under Consideration Holds Steady at 30
NEXT POST →
Files Under pCPA Consideration for Greater Than 6 Months is the Highest its Been in a Year

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

Pre-Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Social
Connect & Follow:
Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Highly Productive Month for pCPA Initiations
Learn More
Learn More